In contrast, tovorafenib, another pan‐RAF inhibitor, did not show responses in the Phase I NCT01425008 study in patients with NRASmut melanoma (n = 17) and nine patients had a best response of SD [187]. The gene discussed is RAF1; the disease is melanoma.